<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fludeoxyglucose F-18: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fludeoxyglucose F-18: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fludeoxyglucose F-18: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="17075" href="/d/html/17075.html" rel="external">see "Fludeoxyglucose F-18: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52871371"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Atlantiscan;</li>
<li>Cyclodx;</li>
<li>FluGlucoScan;</li>
<li>FluorOHmet (Citrate);</li>
<li>FluorOHmet (Phosphate);</li>
<li>Glucovision;</li>
<li>Glucovision (Citrate);</li>
<li>Glucovision (Phosphate)</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13172595"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F13172699"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1b2cfa95-0b17-4b6d-8cfd-2b2da4940a43">Positron emission tomography imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Positron emission tomography (PET) imaging (oncology, cardiology, and neurology settings):</b>
<b>IV</b> (based on 70 kg patient): 5 to 10 mCi (185 to 370 MBq).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991156"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988513"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F56892915"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F13172698"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1b2cfa95-0b17-4b6d-8cfd-2b2da4940a43">Positron emission tomography imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Positron emission tomography (PET) imaging</b>
<b>(neurology setting):</b> IV: 2.6 mCi (96.2 MBq); optimal dose adjustment on body size or weight has not been determined</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51110623"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51110624"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F13172579"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Endocrine &amp; metabolic: Hyper-/hypoglycemia (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: </p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Transient hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Transient alkaline phosphatase increased</p></div>
<div class="block coi drugH1Div" id="F25593614"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to fludeoxyglucose or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F13172507"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes mellitus: In patients in the oncology or neurology setting with inadequately regulated blood glucose levels, suboptimal imaging may occur; consider medical therapy and laboratory testing to assure 2 days of normal blood glucose prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patient information: Instruct patients in oncology or neurology settings to fast 4 to 6 hours prior to administration. In the cardiology setting, intake of 50 to 75 grams of glucose-containing foods or liquids will facilitate localization of cardiac ischemia. Encourage patients to adequately hydrate for 4 hours prior to administration; patients should void when imaging is complete and as often as possible thereafter for at least 1 hour to minimize bladder exposure.</p></div>
<div class="block foc drugH1Div" id="F53390080"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20-300 MCI/ML (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20-500 MCI/ML (1 ea)</p></div>
<div class="block geq drugH1Div" id="F52980433"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F53559971"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Fludeoxyglucose F 18 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20-300 mci/mL (per each): $222.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20-500 mci/mL (per each): $365.17</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871372"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cyclodx: 0.5-232 GBq (18 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FluGlucoScan: 0.5 GBq (20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glucovision (Citrate): 453 GBQ (10 mL, 30 mL) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glucovision (Phosphate): 540 GBQ (10 mL, 30 mL) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4240 mCi (10 mL, 20 mL, 30 mL); 18.5 mCi/mL (30 mL); 0.5 GBq (10 mL, 16 mL, 20 mL, 29 mL); 0.5-232 GBq (29 mL); 1-441 GBq (10 mL, 30 mL); 10-200 MCI/ML (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glucovision: 453 GBQ (1 mL, 3 mL, 5 mL) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glucovision (Phosphate): 540 GBQ (1 mL, 3 mL, 5 mL) [contains alcohol, usp]</p></div>
<div class="block adm drugH1Div" id="F20217880"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer as an IV injection. Initiate imaging within 40 minutes of administration; obtain static emission images 30 to 100 minutes after injection. Encourage patients to adequately hydrate for 4 hours prior to administration. Instruct patients in oncology or neurology settings to fast 4 to 6 hours prior to administration; also, consider medical therapy or laboratory testing to ensure at least 2 days of normoglycemia prior to administration. In the cardiology setting, administering 50 to 75 g of glucose-containing foods or liquids prior to administration will facilitate localization of cardiac ischemia. To minimize bladder exposure, patients should void when imaging is complete and as often as possible thereafter for at least 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal. Waterproof gloves should be worn and effective shielding should be used during handling and administration.</p></div>
<div class="block admp drugH1Div" id="F52614172"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: <b>Note: </b>Radiopharmaceutical; use appropriate precautions for handling and disposal. Waterproof gloves should be worn and effective shielding should be used during handling and administration.</p>
<p style="text-indent:-2em;margin-left:2em;">PET imaging (Neurology setting): Administer as an IV injection. Initiate imaging within 40 minutes of administration. Encourage patients to adequately hydrate for 4 hours prior to administration. Instruct patients to fast 4 to 6 hours prior to administration; also, consider medical therapy or laboratory testing to ensure at least 2 days of normoglycemia prior to administration. To minimize bladder exposure, patients should void when imaging is complete and as often as possible thereafter for at least 1 hour.</p></div>
<div class="block use drugH1Div" id="F13172458"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Positron emission tomography (PET) imaging:</b> Fluorinated deoxyglucose used in conjunction with positron emission tomography (PET) imaging for assessment of abnormal glucose metabolism to assist in evaluating malignancy in patients with known or suspected abnormalities found by other testing modalities or in patients with diagnosis of cancer; in conjunction with myocardial perfusion imaging to identify left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction; to detect areas in the brain with abnormal glucose metabolism linked with foci of epileptic seizures</p></div>
<div class="block mst drugH1Div" id="F13255249"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F56202562"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56202559"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: May diminish the diagnostic effect of Fludeoxyglucose F 18. Management: Consider holding metformin for 48 hours or longer prior to PET scans using fludeoxyglucose F18 (FDG-F18) when imaging of the colon or intestine is required. Consider increased monitoring of blood glucose when metformin is held.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F13172517"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Fludeoxyglucose F 18 crosses the placenta and can be detected in the fetus.</p>
<p style="text-indent:0em;margin-top:2em;">The amount of fludeoxyglucose F 18 absorbed by the fetus is greater when exposure is via positron emission tomography (PET)/CT versus PET alone. Exposure also varies by gestational age, with higher exposure occurring earlier in pregnancy. Exposure can be decreased with more frequent voiding (Takalkar 2011; Zanotti-Fregonara 2015; Zanotti-Fregonara 2017). Adverse fetal effects or radiation-related risks have not been identified for diagnostic procedures involving &lt;50 mGy. Long-term effects to a child following in utero exposure are not known.</p></div>
<div class="block brc drugH1Div" id="F20688336"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Fludeoxyglucose F 18 is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The uptake of fludeoxyglucose F 18 by breast tissue may vary in relation to maternal age, timing of menstrual cycle, and presence of mastitis. Uptake may differ between breasts in women who are breastfeeding (Abhyankar 2012; Dong 2016; Hicks 2001; Ko 2013; Shor 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, benefits of breastfeeding to the infant, and benefits of treatment to the mother. To decrease radiation exposure to the infant, the infant should be fed prior to the injection and close breast contact should be avoided for 9 to 12 hours after the maternal injection of fludeoxyglucose F 18. Although the manufacturer recommends lactating women express and discard milk during this time, milk collected during this period may be used to bottle feed to avoid close contact with the breast (Jamar 2013).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F26529878"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Barnascan | Flucis | Fludesoxiglucosa | Fluotracer | Gluscan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Glucotep</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Pozitronscan fdg</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fdg scan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Radiljos</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22691511">
<a name="22691511"></a>Abhyankar A, Joshi J, Basu S. FDG uptake in unilateral breast related to breastfeeding practice in a patient of pulmonary hydatid cyst. <i>Clin Nucl Med.</i> 2012;37(7):676-678. doi: 10.1097/RLU.0b013e31824d210d.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludeoxyglucose-f-18-drug-information/abstract-text/22691511/pubmed" id="22691511" target="_blank">22691511</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cyclodx (fludeoxyglucose F 18) [product monograph]. Sherbrooke, Québec, Canada: Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke; April 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26975010">
<a name="26975010"></a>Dong A, Wang Y, Lu J, Zuo C. Spectrum of the breast lesions with increased 18F-FDG uptake on PET/CT.<i> Clin Nucl Med.</i> 2016;41(7):543-557. doi: 10.1097/RLU.0000000000001203.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludeoxyglucose-f-18-drug-information/abstract-text/26975010/pubmed" id="26975010" target="_blank">26975010</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Fludeoxyglucose F 18 (fludeoxyglucose f-18 injection) [prescribing information]. Manhasset, NY: The Feinstein Institute for Medical Research; June 2019.</div>
</li>
<li>
<div class="reference">
                  FluorOHmet (fludeoxyglucose f-18 injection) [product monograph]. Ottawa, Ontario, Canada: University of Ottawa Heart Institute National; January 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11483686">
<a name="11483686"></a>Hicks RJ, Binns D, Stabin MG. Pattern of uptake and excretion of (18)F-FDG in the lactating breast. <i>J Nucl Med.</i> 2001;42(8):1238-1242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludeoxyglucose-f-18-drug-information/abstract-text/11483686/pubmed" id="11483686" target="_blank">11483686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23359660">
<a name="23359660"></a>Jamar F, Buscombe J, Chiti A, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. <i>J Nucl Med</i>. 2013;54(4):647-658. doi: 10.2967/jnumed.112.112524.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludeoxyglucose-f-18-drug-information/abstract-text/23359660/pubmed" id="23359660" target="_blank">23359660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23690704">
<a name="23690704"></a>Ko KH, Jung HK, Jeon TJ. Diffuse intense 18F-FDG uptake at PET in unilateral breast related to breastfeeding practice.<i> Korean J Radiol.</i> 2013;14(3):400-402. doi: 10.3348/kjr.2013.14.3.400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludeoxyglucose-f-18-drug-information/abstract-text/23690704/pubmed" id="23690704" target="_blank">23690704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12072789">
<a name="12072789"></a>Shor M, Dave N, Reddy M, Ali A. Asymmetric FDG uptake in a lactating breast. <i>Clin Nucl Med.</i> 2002;27(7):536. doi: 10.1097/00003072-200207000-00019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludeoxyglucose-f-18-drug-information/abstract-text/12072789/pubmed" id="12072789" target="_blank">12072789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21680687">
<a name="21680687"></a>Takalkar AM, Khandelwal A, Lokitz S, Lilien DL, Stabin MG. 18F-FDG PET in pregnancy and fetal radiation dose estimates. <i>J Nucl Med</i>. 2011;52(7):1035-1040. doi:10.2967/jnumed.110.085381<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludeoxyglucose-f-18-drug-information/abstract-text/21680687/pubmed" id="21680687" target="_blank">21680687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26089550">
<a name="26089550"></a>Zanotti-Fregonara P, Laforest R, Wallis JW. Fetal radiation dose from 18F-FDG in pregnant patients imaged with PET, PET/CT, and PET/MR. <i>J Nucl Med</i>. 2015;56(8):1218-1222. doi: 10.2967/jnumed.115.157032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludeoxyglucose-f-18-drug-information/abstract-text/26089550/pubmed" id="26089550" target="_blank">26089550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28572491">
<a name="28572491"></a>Zanotti-Fregonara P, Stabin MG. New fetal radiation doses for (18)F-FDG based on human data. <i>J Nucl Med</i>. 2017;58(11):1865-1866. doi: 10.2967/jnumed.117.195404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludeoxyglucose-f-18-drug-information/abstract-text/28572491/pubmed" id="28572491" target="_blank">28572491</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16795 Version 97.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
